[Ip-health] DNDi Joins WIPO Open Innovation Platform But Calls for More Ambitious Provisions

Rachel M. Cohen rachel.cohen72 at gmail.com
Wed Oct 26 05:48:23 PDT 2011


DNDi Joins WIPO Open Innovation Platform But Calls for More Ambitious
Provisions for Innovation and Access

 

Geneva, Switzerland, 26 October 2011 – The Drugs for Neglected Diseases
initiative (DNDi) welcomes the World Intellectual Property Organization
(WIPO) initiative to create an open innovation platform – in the form of a
searchable public database – to make intellectual property (IP), including
compounds and regulatory data, for neglected disease innovation available
for licensing. The initiative, called Re:Search, is being launched today in
Geneva. 

 

This initiative confirms a recent growing trend of openness in the
management of IP for global health. After the Medicines Patent Pool for HIV
launched by UNITAID and the Pool for Open Innovation for Neglected Tropical
Diseases (NTDs) launched by GlaxoSmithKline (GSK), WIPO Re:Search represents
an additional move towards more open mechanisms that have the potential to
facilitate and foster sharing of IP and knowledge for neglected disease
innovation. 

 

DNDi joins WIPO Re:Search as a Provider and likely User. It has committed to
providing raw data to WIPO Re:Search, including information on development
of drugs for leishmaniasis and human African trypanosomiasis, both of which
are fatal parasitic diseases.

 

This mechanism has the potential to avoid duplication in research and to
reduce costs and development timelines for the benefit of patients. However,
while DNDi welcomes the initiative, it points to two elements considered
essential to ensure innovation and access in neglected-disease endemic
countries:

 

‘Firstly, WIPO and other important players engaged in global health should
take a step further in terms of access, especially by including not only the
least developed countries but all neglected disease-endemic countries’, said
Dr Bernard Pécoul, Executive Director of DNDi. ‘Secondly, we need to aim for
more transparency in licensing practices that have a public health goal. We
have to go beyond the minimum,’ he added. 

 

Since its inception, DNDi has advocated for open innovation. In practice, it
brokers very ambitious and clear agreements to ensure equitable access in
neglected disease-endemic countries with several pharmaceutical partners.
DNDi will continue to negotiate for the best conditions for neglected
patients and to promote more open innovation for neglected diseases.

 

Part of DNDi’s mission is to encourage and support follow-on research for
neglected diseases by the research community. It will use WIPO Re:Search, in
addition to other public databases, to share, as much as possible, research
data generated in partnership with public and private partners. 

 


About Drugs for Neglected Diseases initiative (DNDi) 



DNDi is a not-for-profit research and development organization working to
deliver new treatments for neglected diseases, in particular human African
trypanosomiasis, leishmaniasis, Chagas disease, malaria, and, with the
recent expansion of its portfolio, specific helminth infections and
pediatric HIV. DNDi was established in 2003 by Doctors Without
Borders/Médecins Sans Frontières (MSF), the Oswaldo Cruz Foundation from
Brazil, the Indian Council for Medical Research, the Kenya Medical Research
Institute, the Ministry of Health of Malaysia, and the Pasteur Institute of
France. The UNICEF/UNDP/World Bank/World Health Organization’s Special
Programme for Research and Training in Tropical Diseases (TDR) serves as a
permanent observer. 

 

Contact:
Gabrielle Landry Chappuis

Head of Communication and Advocacy, DNDi
Tel.: +41 79 309 3910   

E-mail: glandry at dndi.org 
www.dndi.org

 

 




More information about the Ip-health mailing list